UCB |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121.2 EUR | +1.13% |
|
-0.49% | +53.68% |
| Apr. 11 | Berenberg Reiterates UCB's Purchase Rating, Raises PT | MT |
| Apr. 11 | UCB : Berenberg, Buy, raises its price target | CF |
Presenter SpeechAntje Witte (Executives)Welcome to the UCB Full Year 2022 Capital Market Call....
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.
Sector
Pharmaceuticals
Calendar
2024-07-25
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
119.9
EUR
Average target price
125.5
EUR
Spread / Average Target
+4.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +53.68% | 24.52B | |
| -2.35% | 89.33B | |
| +3.29% | 41.19B | |
| -15.40% | 31.87B | |
| -14.35% | 15.68B | |
| -6.52% | 12.34B | |
| -39.65% | 12.23B | |
| +6.22% | 8.83B | |
| -6.43% | 8.28B | |
| -0.57% | 7.52B |
- Stock Market
- Equities
- UCB Stock
- News UCB
- Transcript : UCB SA, 2022 Earnings Call, Feb 22, 2023